U.S. market Closed. Opens in 2 days 1 hour 35 minutes

KYMR | Kymera Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue78.59M46.83M72.83M34.03M2.93MN/A
Cost of Revenue3.56M2.98M2.40M62.10M825.00KN/A
Gross Profit75.03M43.85M70.44M-28.07M2.11MN/A
Operating Expenses244.12M208.08M173.36M80.34M45.14M21.45M
Selling, General & Admin55.04M43.83M36.34M18.23M7.98M3.77M
Research & Development189.08M164.25M137.02M62.10M37.16M17.68M
Other Operating ExpensesN/AN/AN/AN/AN/AN/A
Operating Income-165.53M-161.26M-100.53M-46.30M-42.20M-21.45M
Other Expenses / Income18.57M6.45M313.00K711.00K959.00K-16.00K
Before Tax Income-146.96M-154.81M-100.22M-45.59M-41.25M-21.47M
Income Tax Expenses18.76M-2.98M-2.22M-1.65M46.00KN/A
Net Income-146.96M-151.83M-98.00M-43.95M-41.29M-21.47M
Interest Expenses196.00K176.00K175.00K115.00K46.00K16.00K
Basic Shares Outstanding58.37M53.93M47.99M17.35M44.53M20.14M
Diluted Shares Outstanding58.37M53.93M47.99M17.35M44.53M20.14M
EBITDA-143.20M-154.63M-100.04M-45.48M-40.38M-21.25M
EBITDA Margin-182.21%-330.23%-137.36%-133.63%-1,376.11%0.00%
EBIT-128.00M-154.63M-100.04M-45.48M-41.20M-21.45M
EBIT Margin-162.87%-330.23%-137.36%-133.63%-1,404.23%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙